
argenx (ARGX) Stock Forecast & Price Target
argenx (ARGX) Analyst Ratings
Bulls say
argenx is a biopharmaceutical company with a positive outlook, as they have received FDA approvals for their lead product Vyvgart for multiple indications, are expanding their pipeline to other rare autoimmune diseases, and have a strong competitive position in the market. Their financials are promising, with an expected 8× multiple to efgartigimod sales in MG and CIDP by 2028, as well as plans for future FcRn and first-in-class molecule development in 2026. Risks to their success include potential competition and unforeseen safety issues, but their strong leadership and commitment to innovation make them a promising investment opportunity.
Bears say
argenx is focused on developing innovative antibody-based therapies for rare autoimmune diseases, with their flagship product Vyvgart (efgartigimod) receiving FDA approval for multiple indications. While the company has reported strong financial performance and expansion into new markets, their pipeline products are still in early stages and there are risks related to potential competition. Additionally, the dependence on a few key products for a significant portion of their revenue leaves the company vulnerable to any setbacks or failures in clinical trials.
This aggregate rating is based on analysts' research of argenx and is not a guaranteed prediction by Public.com or investment advice.
argenx (ARGX) Analyst Forecast & Price Prediction
Start investing in argenx (ARGX)
Order type
Buy in
Order amount
Est. shares
0 shares